D&D Pharmatech Inc.
Clinical-stage biopharma developing GLP-1 therapies for metabolic and neurodegenerative diseases.
347850 | KO
Overview
Corporate Details
- ISIN(s):
- KR7347850000
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시
- Website:
- http://www.ddpharmatech.com/
- Sector:
- Manufacturing
Description
D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.2 KB | ||
| 2025-12-16 00:00 |
주식매수선택권부여에관한신고
|
Korean | 17.9 KB | ||
| 2025-09-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2025-09-09 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2025-08-14 00:00 |
반기보고서 (2025.06)
|
Korean | 1.6 MB | ||
| 2025-07-16 00:00 |
기업설명회(IR)개최
|
Korean | 6.8 KB | ||
| 2025-07-09 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 64.4 KB | ||
| 2025-06-27 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 180.8 KB | ||
| 2025-06-20 00:00 |
증권발행결과(자율공시)
|
Korean | 6.1 KB | ||
| 2025-06-19 00:00 |
기타경영사항(자율공시) (국책과제 선정(국가신약개발사업(R&D) (대사이상 관련 지방간염(MASH) 치료제 DD01 개…
|
Korean | 7.9 KB | ||
| 2025-06-17 00:00 |
기업설명회(IR)개최
|
Korean | 6.8 KB | ||
| 2025-06-16 00:00 |
투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline …
|
Korean | 12.8 KB | ||
| 2025-06-13 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2025-06-13 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB | ||
| 2025-06-13 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB |
Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for D&D Pharmatech Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
